Story perspectives

Trump Administration's FDA Rollback Threatens Diversity in Trials

1/26/2025

27 4

Summary

Story summary

The Trump administration's decision to eliminate FDA guidance on diversity in clinical trials raises serious concerns about the representation of underrepresented groups. This move is part of a larger trend to roll back diversity initiatives across federal agencies, prompting experts to warn that such actions could result in ineffective drug approvals for diverse populations in the U.S.

History

Historical Context

The Trump administration's elimination of FDA guidance on diversity in clinical trials echoes historical patterns of marginalizing minority health issues. In the 1980s, during the AIDS crisis, marginalized groups faced significant barriers in clinical research. The current rollback of diversity initiatives risks repeating past mistakes, potentially leading to ineffective treatments for diverse populations, undermining progress made in inclusive healthcare practices since then.

1 of 2

Story summary

The Trump administration's decision to eliminate FDA guidance on diversity in clinical trials raises serious concerns about the representation of underrepresented groups. This move is part of a larger trend to roll back diversity initiatives across federal agencies, prompting experts to warn that such actions could result in ineffective drug approvals for diverse populations in the U.S.

1 / 2